vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
30.21
-0.52 (-1.69%)
At close: Sep 25, 2026, 4:00 PM EDT
30.09
-0.12 (-0.40%)
After-hours: Sep 25, 2026, 4:10 PM EDT
vTv Therapeutics Employees
vTv Therapeutics had 26 employees as of December 31, 2025. The number of employees increased by 3 or 13.04% compared to the previous year.
Employees
26
Change (1Y)
3
Growth (1Y)
13.04%
Revenue / Employee
$1,416,885
Profits / Employee
-$182,923
Market Cap
375.35M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 26 | 3 | 13.04% |
| Dec 31, 2024 | 23 | 7 | 43.75% |
| Dec 31, 2023 | 16 | 3 | 23.08% |
| Dec 31, 2022 | 13 | 4 | 44.44% |
| Dec 31, 2021 | 9 | -16 | -64.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcturus Therapeutics Holdings | 111 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Orchestra BioMed Holdings | 86 |
| Agenus | 81 |
| Zura Bio | 40 |
| Inhibikase Therapeutics | 35 |
| Fennec Pharmaceuticals | 35 |
VTVT News
- 11 days ago - vTv Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 12 days ago - vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - vTv Therapeutics to Participate in September Investor Conferences - GlobeNewsWire
- 25 days ago - vTv Therapeutics initiated with an Outperform at LifeSci Capital - TheFly
- 7 weeks ago - vTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright - TheFly
- 7 weeks ago - vTv Therapeutics reports Q2 EPS ($1.05), consensus (99c) - TheFly
- 7 weeks ago - vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - vTv Therapeutics Quarterly report: Q2 2026 - Filings